Foghorn Therapeutics Inc (FHTX) Implied Volatility Current

Tracking FHTX implied volatility helps you identify when options premiums on Foghorn Therapeutics Inc are historically cheap or expensive, and where the best trades are hiding. Foghorn Therapeutics Inc implied volatility reflects the market's expectation of future price movement: when FHTX IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Foghorn Therapeutics Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For FHTX, tracking metrics like FHTX IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on FHTX signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma.

The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where FHTX implied volatility sits today versus where it has been. Our scanner ranks Foghorn Therapeutics Inc implied volatility against its historical range, surfaces extremes in FHTX IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Foghorn Therapeutics Inc IV is rich or cheap — measure it, then act on it.